Literature DB >> 10619490

Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen.

P E Budtz1.   

Abstract

Studies on growth regulation in vitro to a large extent rely on comparison of growth curves. However, these do not discriminate between the relative contributions of the mitotic rate and the apoptotic rate to the net growth rate. In the present study, differential effects of 17beta-oestradiol (E2, 10(-8) M) and/or tamoxifen (TAM, 10(-6) M) on proliferation and apoptosis have been examined and related to growth curves of a subline of the human breast cancer cell line MCF-7 adapted to grow at low serum concentrations. Counting of cells and scoring of labelling and apoptotic indices were performed at the start of the experiment and 3, 6 and 9 days after changing the experimental media. The results demonstrate that apoptosis in this subline is constitutively expressed, that E2 protects (at least partly) against apoptosis and stimulates proliferation, resulting in an increased (net) growth rate, and final cell pool size, and that TAM has a weak cytostatic effect and stimulates apoptosis strongly, resulting in a decreased (net) growth rate and final cell pool size. When E2 and TAM are added simultaneously to the medium, the cytotoxic effect of TAM is partly counterbalanced by the protective role of E2, resulting in a reduced apoptotic rate that, however, is at a higher level than in cultures grown with E2 only. As the cytostatic role of TAM is partly abolished by E2, the combined effect of E2 and TAM results in a final (net) growth rate and cell pool size intermediary to cells grown with E2 or TAM alone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619490      PMCID: PMC6726337          DOI: 10.1046/j.1365-2184.1999.3250289.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  44 in total

1.  Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells.

Authors:  A Gulino; G Barrera; A Vacca; A Farina; C Ferretti; I Screpanti; M U Dianzani; L Frati
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

Review 2.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.

Authors:  M C Pike; D V Spicer; L Dahmoush; M F Press
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

3.  Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy.

Authors:  W Bursch; A Ellinger; H Kienzl; L Török; S Pandey; M Sikorska; R Walker; R S Hermann
Journal:  Carcinogenesis       Date:  1996-08       Impact factor: 4.944

4.  The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the estrogen receptor.

Authors:  S Bardon; F Vignon; D Derocq; H Rochefort
Journal:  Mol Cell Endocrinol       Date:  1984-05       Impact factor: 4.102

5.  Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare.

Authors:  R R Reddel; R L Sutherland
Journal:  Eur J Cancer Clin Oncol       Date:  1984-11

6.  Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells.

Authors:  V Cavailles; P Augereau; M Garcia; H Rochefort
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

7.  Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.

Authors:  N Kyprianou; H F English; N E Davidson; J T Isaacs
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

8.  Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells.

Authors:  C K Watts; K J Sweeney; A Warlters; E A Musgrove; R L Sutherland
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture.

Authors:  Y Berthois; J A Katzenellenbogen; B S Katzenellenbogen
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

10.  Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.

Authors:  A E Lykkesfeldt; M W Madsen; P Briand
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701

View more
  7 in total

1.  Tamoxifen induces apoptotic neutrophil efferocytosis in horses.

Authors:  C Olave; N Morales; B Uberti; C Henriquez; J Sarmiento; A Ortloff; H Folch; G Moran
Journal:  Vet Res Commun       Date:  2018-01-02       Impact factor: 2.459

2.  G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells.

Authors:  Akira Ichikawa; Jiro Ando; Koichi Suda
Journal:  Hum Cell       Date:  2008-05       Impact factor: 4.174

3.  Apoptotic effects of tamoxifen on leukocytes from horse peripheral blood and bronchoalveolar lavage fluid.

Authors:  J Sarmiento; B Perez; N Morales; C Henriquez; L Vidal; H Folch; J S Galecio; G Morán
Journal:  Vet Res Commun       Date:  2013-07-12       Impact factor: 2.459

4.  Tamoxifen Action in ER-Negative Breast Cancer.

Authors:  Subrata Manna; Marina K Holz
Journal:  Sign Transduct Insights       Date:  2016-02-10

5.  Tamoxifen and its metabolites induce mitochondrial membrane depolarization and caspase-3 activation in equine neutrophils.

Authors:  Alejandro Albornoz; Natalia Morales; Benjamin Uberti; Claudio Henriquez; Rafael A Burgos; Pablo Alarcon; Gabriel Moran
Journal:  Vet Med Sci       Date:  2020-06-17

Review 6.  Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy.

Authors:  Wenlin Shao; Myles Brown
Journal:  Breast Cancer Res       Date:  2003-11-07       Impact factor: 6.466

7.  Tamoxifen inhibits chemokinesis in equine neutrophils.

Authors:  Natalia Morales; Claudio Henriquez; Jose Sarmiento; Benjamin Uberti; Gabriel Moran
Journal:  Ir Vet J       Date:  2018-10-23       Impact factor: 2.146

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.